By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

Key Statistics

Ownership: Public

Web Site: Halozyme
Employees: 152
Symbol: HALO

Company News
Halozyme (HALO) To Present At Upcoming Healthcare Conferences 11/25/2015 6:48:20 AM
SoCal's Halozyme (HALO) To Expand With A Satellite Office In San Francisco 11/18/2015 6:22:06 AM
Halozyme (HALO) Reports Third Quarter 2015 Financial Results 11/10/2015 8:08:17 AM
First Patient Dosed In Clinical Trial Of Halozyme (HALO) Investigational Drug PEGPH20 In Combination With Merck & Co. (MRK) Immuno-Oncology Drug KEYTRUDA 11/5/2015 7:23:01 AM
Halozyme (HALO) To Present At The Credit Suisse Healthcare Conference 11/4/2015 10:03:29 AM
Halozyme (HALO) Announces First Clinical Dosing Of Janssen Biotech Inc. (JNJ)'s Daratumumab Using ENHANZE Technology 11/4/2015 6:48:43 AM
Halozyme (HALO) Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology 10/29/2015 6:59:55 AM
Halozyme (HALO) To Host Third Quarter 2015 Financial Results Conference Call 10/19/2015 3:42:05 PM
Halozyme (HALO) Appoints Michael J. Labarre As Chief Scientific Officer 8/24/2015 7:51:12 AM
Halozyme (HALO) Reports Second Quarter 2015 Financial Results 8/11/2015 10:06:09 AM